China’s innovative drug exports accelerate with record overseas licensing deals
Xinhua News Agency reports that China’s outbound licensing transactions for innovative drugs exceeded 60 billion US dollars in the first quarter of 2026, nearly half of the full-year volume recorded in 2025. The robust trading momentum continues, enabling China’s pharmaceutical innovation to shift from passive overseas cooperation to proactive global layout.
The sector has entered a new development phase featuring large-value deals and early-stage global collaboration. Major landmark cooperation agreements have been inked since the start of 2026. A January partnership between Chinese and international pharmaceutical enterprises on long-acting polypeptide drugs and technical platforms reached a potential value of 18.5 billion US dollars. Another early-stage global joint research project in oncology and immunology secured a maximum value of 8.85 billion US dollars.
Industrial data shows that down payment funds for outbound licensing of Chinese innovative drugs reached 3.3 billion US dollars in the first three months of 2026. The full-year outbound transaction volume hit a record high of over 130 billion US dollars in 2025. Authorities confirm that China’s pipeline of innovative drugs under research accounts for one third of the global total, reflecting substantial improvement in independent research capabilities.
Overseas cooperation models have undergone tangible upgrades. Cross-border collaboration now extends to pre-clinical and Phase I projects. Over half of China’s outbound drug licensing deals in 2025 targeted early-stage assets with novel targets and clear pharmacological mechanisms, gaining wide recognition among multinational pharmaceutical corporations. Cooperation forms have expanded beyond single-product licensing, covering technology platform export, co-development and commercialisation, and joint venture models.
Strong industrial competitiveness and global market demand jointly drive the booming outbound expansion. Nearly 20 domestically developed innovative drugs have obtained market approval in 2026, covering lung cancer, psoriasis, renal anaemia and other major and common diseases. The world’s first integrin-targeting nuclear medicine diagnostic injection developed by Chinese researchers has been launched for auxiliary detection of lymph node metastasis in lung cancer patients.
Continuous institutional optimisation consolidates industrial innovation vitality. China has streamlined drug review and approval procedures, stabilised market expectations through medical insurance negotiations, and attracted high-end overseas talents to join local research teams. A standardised national drug pricing registration system supports enterprises in building diversified global pricing frameworks, offering sufficient policy space for high-level pharmaceutical innovation.
Global pharmaceutical giants face patent expirations and pipeline gaps, creating strong demand for high-quality innovative pharmaceutical assets. Multinational enterprises have deepened cooperation with Chinese partners through joint venture establishment and increased local investment. New overseas-funded innovation centres and production upgrading projects have been launched in China’s pharmaceutical hubs.
Current licensing agreements generally retain Greater China rights for domestic enterprises, ensuring independent control of domestic pricing and supply systems. Outbound licensing helps domestic enterprises recycle research funds, accumulate global operational experience, and realise risk-sharing with international partners. Driven by national strategic plans for emerging industries, China’s pharmaceutical sector will further advance high-quality, digital and inclusive innovation to deliver advanced medical products worldwide.
